



FDA ADVISORY

No. 2021-0502-A

20 JUL 2022

TO: THE GENERAL PUBLIC

SUBJECT: Amendment to FDA Advisory No. 2021-0502 “Public Health Warning Against the Purchase and Use of Cosmetic Product BABYFLO® BABY COLOGNE PINK FANTASY Containing Banned Ingredient/s” dated 05 March 2021

The Food and Drug Administration (FDA) hereby advises the public that the cosmetic product **BABYFLO® BABY COLOGNE PINK FANTASY** as listed in FDA Advisory No. 2021-0502 “Public Health Warning Against the Purchase and Use of Cosmetic Product Containing Banned Ingredient/s dated 05 March 2021 is hereby amended.

The Market Authorization Holder (MAH), Philusa Corporation., has conducted a voluntary recall and complete disposal of specific batch of the cosmetic product affected by the said Advisory whose particulars/details are provided below:

Product Details	Product Image/s
<p>Manufactured by/Company Responsible for Placing the Product in the Market: Philusa Corporation</p> <p>Country of Manufacture: Philippines</p> <p>Lot/Batch Number: C00192 Manufacturing Date: 021820 Expiration Date: 021823</p>	

According to the MAH, the inventory with identified lot/batch number, manufacturing and expiration date are no longer available in the market and have been voluntarily recalled and properly disposed of.



The MAH is urged to strictly comply with FDA implemented laws, rules and regulations and to closely monitor the marketing of the subject products. Nothing in this Advisory shall preclude the FDA from pursuing further actions, as it may deem necessary against the MAH, should the subject product be confirmed to contain banned ingredients.

In view thereof, FDA Advisory No. 2021-0502 is hereby amended accordingly. To report any suspicious activity and/or product, kindly e-mail us via ereport@fda.gov.ph. For more information and inquiries, please e-mail us at cchuhsrr@fda.gov.ph or call us at the Center for Cosmetics and Household/Urban Hazardous Substances Regulation and Research (CCHUHSRR) hotline **(02) 857-1900 local 8113/8017**.

Dissemination of this advisory to all concerned is hereby requested.


DR. OSCAR G. GUTIERREZ, JR.
Officer-in-Charge Director General

DTN: 20220706101618